Physician
Oncology
Dr. Agop Y. Bedikian, MD
|
|
Give Review
Agop Bedikian practices Oncology. Dr. Agop Y. Bedikian is a published doctor and has 34 publications published. The lastest was: 'Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma.' He accepts all Medicare patients.
Publications
- Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced Melanoma.
- Malignant melanoma in teenagers and young adults.
- A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic Melanoma.
- Phase I trial of biochemotherapy with cisplatin, temozolomide, and dose escalation of nab-paclitaxel combined with interleukin-2 and interferon-α in patients with meta...
- Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced Cancer.
- Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced Melanoma and low-normal serum lactate dehydroge...
- Surveillance for Brain metastases in patients receiving systemic therapy for advanced melanoma.
- Chemical Castration of Melanoma Patients Does Not Increase the Frequency of Tumor-specific CD4 and CD8 T Cells After Peptide Vaccination.
- Appearance of New Vemurafenib-associated Melanocytic Nevi on Normal-appearing Skin: Case Series and a Review of Changing or New Pigmented Lesions in Patients with Meta...
- Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients.
- BRAF, NRAS and KIT sequencing Analysis of spindle cell melanoma.
- Delayed Systemic Recurrence of Uveal Melanoma.
- Risk of intracranial hemorrhage with anticoagulation therapy in melanoma patients with Brain metastases.
- Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic Melanoma.
- Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised Melanoma metastases for adoptive T-cell therapy.
- Predictive factors for the development of Brain metastasis in advanced unresectable metastatic melanoma.
- Does complete response to Systemic therapy in patients with stage IV melanoma translate into long-term survival?
- Pharmacokinetics and safety of Marqibo (vincristine sulfate liposomes injection) in Cancer patients with impaired liver function.
- Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the Liver: response, survival, and prognostic factors.
- A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with Systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tu...
- Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic Malignant melanoma.
- Biochemotherapy in patients with advanced head and neck mucosal Melanoma.
- Prognostic factors that determine the long-term survival of patients with unresectable metastatic Melanoma.
- Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival.
- Challenges of chemosensitivity testing.
- Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic Melanoma patients.
- Metastatic uveal Melanoma therapy: current options.
- A phase II trial of arsenic trioxide in patients with metastatic Melanoma.
- Pilot study of high-dose, concurrent biochemotherapy for advanced Melanoma.
- Biochemotherapy in patients with metastatic anoRectal mucosal melanoma.
- Sphincter-sparing local excision and adjuvant radiation for Anal-rectal melanoma.
- Sequential biochemotherapy versus chemotherapy for metastatic Melanoma: results from a phase III randomized trial.
- Adjuvant irradiation for axillary metastases from Malignant melanoma.
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
University of Texas MD Anderson Cancer Center -
Washington University - Barnes-Jewish Hospital -
American University of Beirut Faculty of Medicine
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1518066521 | |
| NPPES Provider LastName | BEDIKIAN | |
| NPPES Provider FirstName | AGOP | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 159.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 14.0 | |
| Percent Opioid Claims | 8.81 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518066521 |
| Last Name Of The Provider | BEDIKIAN |
| First Name Of The Provider | AGOP |
| View All |
Similar Doctors
|
|
Dr. Paul B. Koller, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph A. Ludwig IV, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Martin N. Raber, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Zehra Kapadia, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jianjun Zhang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. George R. Blumenschein Jr., MD |
|
Dr. Philip A. Salem, MD
This Doctor is OpenDoctor Recommended.
|